Sprint Bioscience AB (publ) (STO:SPRINT)
1.845
-0.025 (-1.34%)
Feb 11, 2026, 12:51 PM CET
Sprint Bioscience AB Revenue
Sprint Bioscience AB had revenue of 5.24M SEK in the quarter ending September 30, 2025, a decrease of -64.62%. This brings the company's revenue in the last twelve months to 50.03M, down -18.59% year-over-year. In the year 2024, Sprint Bioscience AB had annual revenue of 66.14M with 27.97% growth.
Revenue (ttm)
50.03M
Revenue Growth
-18.59%
P/S Ratio
3.94
Revenue / Employee
1.73M
Employees
29
Market Cap
197.31M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 66.14M | 14.46M | 27.97% |
| Dec 31, 2023 | 51.69M | 51.60M | 62,171.08% |
| Dec 31, 2022 | 83.00K | -34.95M | -99.76% |
| Dec 31, 2021 | 35.03M | 15.83M | 82.49% |
| Dec 31, 2020 | 19.20M | -14.62M | -43.23% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Magle Chemoswed Holding AB | 300.49M |
| Xbrane Biopharma AB | 259.70M |
| IRLAB Therapeutics AB | 85.56M |
| Bio-Works Technologies AB | 46.43M |
| Elicera Therapeutics AB | 13.70M |
| NextCell Pharma AB | 11.06M |
| Xintela AB | 2.96M |
| Simris Group AB (PUBL) | 2.30M |